Daxor (DXR) Competitors $11.33 +0.70 (+6.59%) As of 09/4/2025 03:38 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DXR vs. INGN, INFU, CVRX, KRMD, MBOT, CV, ELMD, BSGM, LNSR, and PDEXShould you be buying Daxor stock or one of its competitors? The main competitors of Daxor include Inogen (INGN), InfuSystem (INFU), CVRx (CVRX), KORU Medical Systems (KRMD), Microbot Medical (MBOT), CapsoVision (CV), Electromed (ELMD), Biosig Technologies (BSGM), LENSAR (LNSR), and Pro-Dex (PDEX). These companies are all part of the "medical equipment" industry. Daxor vs. Its Competitors Inogen InfuSystem CVRx KORU Medical Systems Microbot Medical CapsoVision Electromed Biosig Technologies LENSAR Pro-Dex Inogen (NASDAQ:INGN) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations. Does the media refer more to INGN or DXR? In the previous week, Daxor had 3 more articles in the media than Inogen. MarketBeat recorded 7 mentions for Daxor and 4 mentions for Inogen. Inogen's average media sentiment score of 0.89 beat Daxor's score of 0.17 indicating that Inogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inogen 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Daxor 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is INGN or DXR more profitable? Daxor has a net margin of 0.00% compared to Inogen's net margin of -7.58%. Daxor's return on equity of 0.00% beat Inogen's return on equity.Company Net Margins Return on Equity Return on Assets Inogen-7.58% -13.77% -8.52% Daxor N/A N/A N/A Do analysts rate INGN or DXR? Inogen currently has a consensus target price of $11.00, indicating a potential upside of 35.47%. Daxor has a consensus target price of $25.00, indicating a potential upside of 120.65%. Given Daxor's stronger consensus rating and higher possible upside, analysts plainly believe Daxor is more favorable than Inogen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inogen 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Daxor 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals believe in INGN or DXR? 89.9% of Inogen shares are owned by institutional investors. Comparatively, 1.3% of Daxor shares are owned by institutional investors. 1.5% of Inogen shares are owned by insiders. Comparatively, 59.5% of Daxor shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has preferable valuation & earnings, INGN or DXR? Daxor has lower revenue, but higher earnings than Inogen. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInogen$335.70M0.65-$35.89M-$1.06-7.66DaxorN/AN/AN/AN/AN/A Which has more volatility and risk, INGN or DXR? Inogen has a beta of 1.78, suggesting that its share price is 78% more volatile than the S&P 500. Comparatively, Daxor has a beta of -0.1, suggesting that its share price is 110% less volatile than the S&P 500. SummaryDaxor beats Inogen on 7 of the 11 factors compared between the two stocks. Get Daxor News Delivered to You Automatically Sign up to receive the latest news and ratings for DXR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DXR vs. The Competition Export to ExcelMetricDaxorMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$51.42M$4.10B$5.75B$9.85BDividend YieldN/A1.26%6.67%4.51%P/E RatioN/A28.8675.9926.43Price / SalesN/A176.66546.95119.09Price / CashN/A27.2737.0558.92Price / BookN/A4.5510.916.06Net IncomeN/A$189.47M$3.29B$266.28M7 Day Performance3.00%-0.08%0.18%-0.32%1 Month Performance13.64%17.35%6.26%3.44%1 Year Performance19.51%15.19%51.55%23.11% Daxor Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DXRDaxor3.6936 of 5 stars$11.33+6.6%$25.00+120.7%+23.6%$51.42MN/A0.0037News CoveragePositive NewsShort Interest ↑Gap DownINGNInogen4.0282 of 5 stars$7.99+3.6%$11.00+37.7%-29.9%$208.48M$335.70M-7.541,030Positive NewsINFUInfuSystem2.5243 of 5 stars$9.92+0.5%$12.50+26.0%+72.8%$202.63M$139.89M165.36410Positive NewsCVRXCVRx1.9906 of 5 stars$7.58+1.7%$14.00+84.7%-13.0%$194.83M$51.29M-3.61160Positive NewsKRMDKORU Medical Systems2.7697 of 5 stars$4.26+1.4%$4.63+8.6%+70.1%$194.19M$33.65M-47.3380Positive NewsMBOTMicrobot Medical2.0222 of 5 stars$3.88-6.7%$9.00+132.0%+305.3%$189.47MN/A-6.6920High Trading VolumeCVCapsoVisionN/A$3.93-1.5%$5.50+39.9%N/A$186.63MN/A0.0090News CoverageELMDElectromed3.0471 of 5 stars$20.66+2.3%$33.50+62.1%+49.3%$173.26M$61.44M27.55160BSGMBiosig Technologies1.6374 of 5 stars$5.27-0.6%$10.00+89.8%+916.5%$166.52M$40K0.0050LNSRLENSAR1.0704 of 5 stars$12.59-0.6%$15.00+19.1%+174.7%$151.09M$53.49M-2.99110Positive NewsPDEXPro-Dex2.5192 of 5 stars$46.71+1.1%$56.00+19.9%+107.0%$150.69M$53.84M16.68140News CoverageEarnings Report Related Companies and Tools Related Companies Inogen Alternatives InfuSystem Alternatives CVRx Alternatives KORU Medical Systems Alternatives Microbot Medical Alternatives CapsoVision Alternatives Electromed Alternatives Biosig Technologies Alternatives LENSAR Alternatives Pro-Dex Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DXR) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daxor Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Daxor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DXR Stock Alerts